Loading...
Search for: clinical-trial--topic
0.006 seconds

    Early detection of immunization: A study based on an animal model using 1H nuclear magnetic resonance spectroscopy

    , Article Pakistan Journal of Biological Sciences ; Volume 14, Issue 3 , 2011 , Pages 195-203 ; 10288880 (ISSN) Zamani, Z ; Arjmand, M ; Tafazzoli, M ; Ghohzadeh, A ; Pourfallah, F ; Sadeghi, S ; Mirzazadeh, R ; Mirkham, F ; Tahen, S ; Iravam, A ; Bayat, P ; Vahabi, F ; Sharif University of Technology
    2011
    Abstract
    Vaccines require a period of at least three months for clinical trials, hence a method that can identify elicitation of immune response a few days after the first dose is a necessity. Evolutionary variable selections are modeling approaches for proper manipulation of available data which were used to set up an animal model for classification of time dependent 'HNMR metabolomic profiles and pattern recognition of fluctuations of metabolites in two groups of male rabbits. One group of rabbits was immunized with human red blood cells and the other used as control. Blood was obtained every 48 h from each rabbit for a period of six weeks and the serum monitored for antibodies and metabolites by... 

    Repurposing the drug, ivermectin, in COVID-19: toxicological points of view

    , Article European Journal of Medical Research ; Volume 27, Issue 1 , 2022 ; 09492321 (ISSN) Shirazi, F. M ; Mirzaei, R ; Nakhaee, S ; Nejatian, A ; Ghafari, S ; Mehrpour, O ; Sharif University of Technology
    BioMed Central Ltd  2022
    Abstract
    The global COVID-19 pandemic has affected the world’s population by causing changes in behavior, such as social distancing, masking, restricting people’s movement, and evaluating existing medication as potential therapies. Many pre-existing medications such as tocilizumab, ivermectin, colchicine, interferon, and steroids have been evaluated for being repurposed to use for the treatment of COVID-19. None of these agents have been effective except for steroids and, to a lesser degree, tocilizumab. Ivermectin has been one of the suggested repurposed medications which exhibit an in vitro inhibitory activity on SARS-CoV-2 replication. The most recommended dose of ivermectin for the treatment of... 

    Chemotherapeutic effects of Apigenin in breast cancer: Preclinical evidence and molecular mechanisms; enhanced bioavailability by nanoparticles

    , Article Biotechnology Reports ; Volume 34 , 2022 ; 2215017X (ISSN) Adel, M ; Zahmatkeshan, M ; Akbarzadeh, A ; Rabiee, N ; Ahmadi, S ; Keyhanvar, P ; Rezayat, S. M ; Seifalian, A. M ; Sharif University of Technology
    Elsevier B.V  2022
    Abstract
    This review highlights using nanotechnology in increasing the bioavailability of AP (Apigenin) to enhance its therapeutic efficacy in breast cancer treatment. Breast cancer is one of the most leading causes of cancer death in women both in developed and developing countries. According to several epidemiological and clinical trial studies that indicate progestin-stimulated breast cancer in post-menopausal women; it is necessary to determine compounds to suppress or attenuate the tumor-promoting effects of progestins in breast cells. For this purpose, using the natural anti-progestins, including AP compared with the chemical ones could be significantly effective due to the lack of toxicities... 

    Nanotechnology in diagnosis and treatment of coronary artery disease

    , Article Nanomedicine ; Volume 11, Issue 5 , 2016 , Pages 513-530 ; 17435889 (ISSN) Karimi, M ; Zare, H ; Bakhshian Nik, A ; Yazdani, N ; Hamrang, M ; Mohamed, E ; Sahandi Zangabad, P ; Moosavi Basri, S. M ; Bakhtiari, L ; Hamblin, M. R ; Sharif University of Technology
    Future Medicine Ltd 
    Abstract
    Nanotechnology could provide a new complementary approach to treat coronary artery disease (CAD) which is now one of the biggest killers in the Western world. The course of events, which leads to atherosclerosis and CAD, involves many biological factors and cellular disease processes which may be mitigated by therapeutic methods enhanced by nanotechnology. Nanoparticles can provide a variety of delivery systems for cargoes such as drugs and genes that can address many problems within the arteries. In order to improve the performance of current stents, nanotechnology provides different nanomaterial coatings, in addition to controlled-release nanocarriers, to prevent in-stent restenosis.... 

    Challenges and future prospects for the delivery of biologics: oral mucosal, pulmonary, and transdermal routes

    , Article AAPS Journal ; Volume 19, Issue 3 , 2017 , Pages 652-668 ; 15507416 (ISSN) Morales, J. O ; Fathe, K. R ; Brunaugh, A ; Ferrati, S ; Li, S ; Montenegro Nicolini, M ; Mousavikhamene, Z ; McConville, J. T ; Prausnitz, M. R ; Smyth, H. D. C ; Sharif University of Technology
    Springer New York LLC  2017
    Abstract
    Biologic products are large molecules such as proteins, peptides, nucleic acids, etc., which have already produced many new drugs for clinical use in the last decades. Due to the inherent challenges faced by biologics after oral administration (e.g., acidic stomach pH, digestive enzymes, and limited permeation through the gastrointestinal tract), several alternative routes of administration have been investigated to enable sufficient drug absorption into systemic circulation. This review describes the buccal, sublingual, pulmonary, and transdermal routes of administration for biologics with relevant details of the respective barriers. While all these routes avoid transit through the... 

    The immunomodulatory effects of probiotics on respiratory viral infections: A hint for COVID-19 treatment?

    , Article Microbial Pathogenesis ; Volume 148 , November , 2020 Mahooti, M ; Miri, S. M ; Abdolalipour, E ; Ghaemi, A ; Sharif University of Technology
    Academic Press  2020
    Abstract
    Respiratory virus infections are among the most prevalent diseases in humans and contribute to morbidity and mortality in all age groups. Moreover, since they can evolve fast and cross the species barrier, some of these viruses, such as influenza A and coronaviruses, have sometimes caused epidemics or pandemics and were associated with more serious clinical diseases and even mortality. The recently identified Coronavirus Disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a Public Health Emergency of International concern and has been associated with rapidly progressive pneumonia. To ensure protection against emerging respiratory tract... 

    CRISPR-Cas, a robust gene-editing technology in the era of modern cancer immunotherapy

    , Article Cancer Cell International ; Volume 20, Issue 1 , September , 2020 Miri, S. M ; Tafsiri, E ; Cho, W. C. S ; Ghaemi, A ; Sharif University of Technology
    BioMed Central Ltd  2020
    Abstract
    Cancer immunotherapy has been emerged as a promising strategy for treatment of a broad spectrum of malignancies ranging from hematological to solid tumors. One of the principal approaches of cancer immunotherapy is transfer of natural or engineered tumor-specific T-cells into patients, a so called "adoptive cell transfer", or ACT, process. Construction of allogeneic T-cells is dependent on the employment of a gene-editing tool to modify donor-extracted T-cells and prepare them to specifically act against tumor cells with enhanced function and durability and least side-effects. In this context, CRISPR technology can be used to produce universal T-cells, equipped with recombinant T cell...